SMITHKLINE BEECHAM's PLANS FOR TUMS WHEN TAGAMET GOES OTC
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE BEECHAM's PLANS FOR TUMS WHEN TAGAMET GOES OTC include continued marketing emphasis on the calcium benefits offered by the antacid, SmithKline Beecham Consumer Healthcare Chairman Harry Grogme told security analysts at a Dec. 12 meeting in New York City. "Our plans remain to invest heavily behind Tums, to position it appropriately in the antacid category so that we continue to invest behind our calcium story," he said.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning